Deakin University
Browse

File(s) under permanent embargo

Immune checkpoint inhibitors for brain metastases

journal contribution
posted on 2017-06-01, 00:00 authored by A C Tan, A B Heimberger, A M Menzies, N Pavlakis, Mustafa Khasraw
PURPOSE OF REVIEW: Metastasis of cancer to the brain typically portends a poor prognosis and often results in significant morbidity, including from the side effects of treatment. More effective therapies for patients with brain metastases are needed. The current treatment paradigm uses multiple modalities, including surgery, radiation, and in some contexts, systemic chemotherapy and immunotherapy. Immune checkpoint inhibitors are increasingly being used to treat extracranial disease, and their effectiveness in the management of brain metastases needs to be understood. RECENT FINDINGS: The evidence for immune checkpoint inhibitors in the management of brain metastases is largely limited to retrospective analyses of melanoma metastases and ipilimumab. Prospective clinical trials of more active agents are under way, and tentative results suggest activity. Immune checkpoint inhibitors have the potential to improve outcomes in patients with brain metastases. Results of current clinical trials will aid in determining the appropriate sequence or combination of local and systemic therapies.

History

Journal

Current oncology reports

Volume

19

Article number

38

Pagination

1 - 12

Publisher

Springer

Location

New York, N.Y.

ISSN

1523-3790

eISSN

1534-6269

Language

eng

Publication classification

C Journal article; C1.1 Refereed article in a scholarly journal

Copyright notice

2017, Springer Science+Business Media New York